OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes
Ryotaro Bouchi, Tatsuya Kondo, Yasuharu Ohta, et al.
Diabetology International (2022) Vol. 14, Iss. 1, pp. 1-14
Open Access | Times Cited: 16
Ryotaro Bouchi, Tatsuya Kondo, Yasuharu Ohta, et al.
Diabetology International (2022) Vol. 14, Iss. 1, pp. 1-14
Open Access | Times Cited: 16
Showing 16 citing articles:
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Akira Fujiyoshi, Shun Kohsaka, Jun Hata, et al.
Circulation Journal (2024) Vol. 88, Iss. 5, pp. 763-842
Open Access | Times Cited: 7
Akira Fujiyoshi, Shun Kohsaka, Jun Hata, et al.
Circulation Journal (2024) Vol. 88, Iss. 5, pp. 763-842
Open Access | Times Cited: 7
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
Sho Furusawa, Hiroshi Nomoto, Chiho Oba‐Yamamoto, et al.
Endocrine Journal (2024) Vol. 71, Iss. 6, pp. 603-616
Open Access | Times Cited: 7
Sho Furusawa, Hiroshi Nomoto, Chiho Oba‐Yamamoto, et al.
Endocrine Journal (2024) Vol. 71, Iss. 6, pp. 603-616
Open Access | Times Cited: 7
Daisuke Yabe, Yoshiyuki Hamamoto, Daiji Kawanami, et al.
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 11, pp. 1566-1577
Open Access | Times Cited: 7
Glycaemic control efficacy of switching from dipeptidyl peptidase‐4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study (SWITCH‐SEMA 2 study)
Sho Furusawa, Hiroshi Nomoto, Hiroki Yokoyama, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 3, pp. 961-970
Closed Access | Times Cited: 11
Sho Furusawa, Hiroshi Nomoto, Hiroki Yokoyama, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 3, pp. 961-970
Closed Access | Times Cited: 11
Ryo Suzuki, Hanan Amadid, Atheline Major‐Pedersen, et al.
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 8, pp. 1047-1056
Open Access | Times Cited: 4
Verification of the Short-Term Impact of Imeglimin on Liver Fibrosis Markers Stratified by Liver Fibrosis Risk in Patients With Type 2 Diabetes
Takumi Tanaka, Takashi Kitao, Motohiro Kubori, et al.
Cureus (2025)
Open Access
Takumi Tanaka, Takashi Kitao, Motohiro Kubori, et al.
Cureus (2025)
Open Access
Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims data
Tetsuya Miwa, S. Yoshida, Akihiro Nakajima, et al.
Diabetology International (2024) Vol. 15, Iss. 3, pp. 483-494
Closed Access | Times Cited: 3
Tetsuya Miwa, S. Yoshida, Akihiro Nakajima, et al.
Diabetology International (2024) Vol. 15, Iss. 3, pp. 483-494
Closed Access | Times Cited: 3
Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G)
Mitsuru Ohsugi, Kosei Eguchi, Julie T Mortensen, et al.
Diabetes Research and Clinical Practice (2023) Vol. 203, pp. 110841-110841
Open Access | Times Cited: 7
Mitsuru Ohsugi, Kosei Eguchi, Julie T Mortensen, et al.
Diabetes Research and Clinical Practice (2023) Vol. 203, pp. 110841-110841
Open Access | Times Cited: 7
Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study
Tomoya Mita, Naoto Katakami, Hidenori Yoshii, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Tomoya Mita, Naoto Katakami, Hidenori Yoshii, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Glycemic control of once-weekly and other administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: a real-world retrospective cohort study
Ruriko Koto, S. Yoshida, Akihiro Nakajima, et al.
Diabetology International (2024) Vol. 15, Iss. 3, pp. 632-637
Closed Access | Times Cited: 1
Ruriko Koto, S. Yoshida, Akihiro Nakajima, et al.
Diabetology International (2024) Vol. 15, Iss. 3, pp. 632-637
Closed Access | Times Cited: 1
Efficacy and safety of once‐weekly insulin icodec versus once‐daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials
Hirotaka Watada, Björg Ásbjörnsdóttir, Tomoyuki Nishida, et al.
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 1
Hirotaka Watada, Björg Ásbjörnsdóttir, Tomoyuki Nishida, et al.
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 1
Urinary α1 microglobulin level is useful for selecting sodium‐glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes
Masaya Koshizaka, Ryoichi Ishibashi, Ko Ishikawa, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 3071-3075
Closed Access | Times Cited: 1
Masaya Koshizaka, Ryoichi Ishibashi, Ko Ishikawa, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 3071-3075
Closed Access | Times Cited: 1
Real‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan
Takeshi Horii, Yoichi Oikawa, Akira Shimada, et al.
Journal of Diabetes Investigation (2023) Vol. 14, Iss. 11, pp. 1262-1267
Open Access | Times Cited: 1
Takeshi Horii, Yoichi Oikawa, Akira Shimada, et al.
Journal of Diabetes Investigation (2023) Vol. 14, Iss. 11, pp. 1262-1267
Open Access | Times Cited: 1
Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan
Daisuke Yabe, Munehide Matsuhisa, Yoko Takahashi, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 3, pp. 705-723
Open Access
Daisuke Yabe, Munehide Matsuhisa, Yoko Takahashi, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 3, pp. 705-723
Open Access
Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus
Chihiro Yoneda, Junji Kobayashi, Nobuichi Kuribayashi
Diabetology International (2024) Vol. 15, Iss. 3, pp. 569-576
Closed Access
Chihiro Yoneda, Junji Kobayashi, Nobuichi Kuribayashi
Diabetology International (2024) Vol. 15, Iss. 3, pp. 569-576
Closed Access
An age-stratified cross-sectional study of antidiabetic and non-antidiabetic drugs prescribed to Japanese outpatients with diabetes
Rena Kuribayashi, Shiori Hasebe, Daisuke Ishida, et al.
Global Health & Medicine (2023) Vol. 5, Iss. 5, pp. 294-300
Open Access
Rena Kuribayashi, Shiori Hasebe, Daisuke Ishida, et al.
Global Health & Medicine (2023) Vol. 5, Iss. 5, pp. 294-300
Open Access
